Provided by Healio
November 7, 2013
WASHINGTON — Eric J. Lawitz, MD, of the Texas Liver Institute at the University of Texas, San Antonio, discusses the results of the LONESTAR-2 trial, presented during the Late-Breaking Abstract session at the Liver Meeting 2013.
The study evaluated the efficacy of 400 mg daily sofosbuvir with pegylated interferon and ribavirin for 12 weeks in a cohort of patients with hepatitis C genotype 2 and 3 who had failed previous therapy with peginterferon and ribavirin, including patients with and without cirrhosis.
The cohort had a sustained virologic response rate of 89%, with high response rates observed among patients with and without cirrhosis. Two virologic failures occurred, both among patients with HCV genotype 3, including one cirrhotic patient and one without cirrhosis.
Nearly all patients experienced adverse events, but the incidence of events did not increase compared with therapy containing peginterferon and ribavirin alone.
Disclosure: Lawitz reports numerous financial disclosures.
For more information:
Lawitz EJ. LB-4. Late-Breaking Abstract Session. Presented at: The Liver Meeting 2013; Nov. 1-5, Washington.